about
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesPKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsPrior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationA randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AMLFunctional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS).A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemiaPhase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment.A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesActivity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.Post-transplant hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment.Ovarian reserve in women treated for acute lymphocytic leukemia or acute myeloid leukemia with chemotherapy, but not stem cell transplantation.Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutationsClinical outcome of patients with acute promyelocytic leukemia and FLT3 mutationsInternational Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis researNon-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes.The role of myeloid growth factors in acute leukemia.The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.Preclinical and clinical activity of ATP mimetic JAK2 inhibitors.Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
P50
Q24648438-2CAE8059-629A-466D-8D3C-AF17D5B1AC83Q27824821-90A79E5B-349E-4D99-B7DE-353E68400D65Q27851467-0FD0A6F7-E0BA-4FCF-BAF2-90441064FCA1Q28203306-5D1A52B7-99C4-4988-9B31-2DBF04E84128Q33402939-3FCBAC97-4486-4C6A-9671-83A70381672EQ33407924-28FC1EC4-73F6-400B-B006-163A161D6DD0Q33421108-3C18F036-979F-4360-9684-0F8C35D1B8C7Q33556923-E1A38F4E-67A7-4F43-AAC8-E6B91FE9DED4Q33591867-F83E7873-2828-44AF-981F-9025CA884CCCQ33697252-178B3129-B30B-4961-AB2A-563165655127Q33822004-C4E4CD11-DB7B-4B54-B119-DB8D5C2263E5Q34022596-DC4333DA-0326-4865-AE4E-6C32BB799F96Q34608688-3E304A6E-253E-487E-BDE7-C9BBE128824DQ34770384-3E829892-DDC5-4AE2-A288-51ED75FF0049Q35039868-2F28BB27-5FF4-43AD-BDBA-395198E7D910Q35093305-130D55DB-CB8B-45E6-9121-3648929CA071Q35552421-BEC47BD6-D522-416A-B67E-E6F3E30E5A8AQ35561988-334626B2-5243-490D-80FD-C206F1D36149Q35690609-3366C86B-DF34-46F5-B6DE-74A13181A261Q35848319-36AFEB57-A783-452C-BB5C-1113E71FD15BQ35861111-BE568A3D-47B1-44B5-AC8D-C127324CAE56Q35883261-05521E39-4C5F-47D0-88AD-94EE43A9F2D2Q36200611-70787A24-E697-4333-B357-9E7529B82D8BQ36288475-5BD00164-6E4B-4BE4-A049-107320B6926DQ36390379-6B34D228-4903-40A7-85CD-370AC2FDCA12Q36400942-C0B4B3F9-5D13-4798-A934-FC269E1C4AA0Q36410195-C56283F9-99E8-4FC7-87E8-2D884251CDB5Q36468734-ADAFC28C-ABB3-4A29-AF02-66D63E2ABE6FQ36625210-E1751D5B-2393-4CA1-8B39-8770177CE60BQ36702208-20D3F142-AD58-49C5-8D7C-C31C128843A4Q36879957-20B9DAB6-2232-42D4-97B1-AB3C41BF50ABQ37075666-941AF287-3654-46EE-9CB3-4997B6AD1587Q37379461-E49CB7AA-FE15-4863-B816-3E46317D57F2Q37526352-217DDB44-1F01-480D-8964-9E58CE9BE9A3Q37672544-DC543805-CD10-4C79-A106-17DDB0CBDB01Q37700292-CA38C95C-919C-4A3D-A3B1-22E9410AA6F2Q37738433-47EE9034-8FE0-489B-A29E-AE2C774379A1Q37802179-362FFFF7-DF0C-421D-B307-0C550985C607Q38392656-27030446-C88F-4DFE-8CD9-6C3EB497C905Q38419665-D55DDA2D-255E-41BC-9868-2AC7BAC549E5
P50
description
onderzoeker
@nl
name
Martha Wadleigh
@ast
Martha Wadleigh
@en
Martha Wadleigh
@es
Martha Wadleigh
@sl
type
label
Martha Wadleigh
@ast
Martha Wadleigh
@en
Martha Wadleigh
@es
Martha Wadleigh
@sl
prefLabel
Martha Wadleigh
@ast
Martha Wadleigh
@en
Martha Wadleigh
@es
Martha Wadleigh
@sl